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A B S T R A C T
We evaluated the efficiency of a six-month outpatient weight loss treatment program combining healthy diet, fat re-
duction, psychological counseling, exercise, and orlistat treatment, by measuring body weight and levels of cardiovascu-
lar risk factors in 476 subjects with BMI over 30 or 28 with increased blood pressure, cholesterol, and sugar at the base-
line and at the end of program. After four weeks of adjustment to a mild low-calorie diet (1600 kcal/day) and counseling,
subjects started receiving orlistat (120 mg TID). The mean weight loss after 6 months was 10.9%. Systolic pressure
dropped by 6.7%, diastolic by 4.2%, fasting blood glucose by 10.1%, and total cholesterol by 9.8%. Only 9 subjects (7.8%)
poorly tolerated the treatment. More men than women were able to maintain the achieved weight loss six months after the
program (70.6% vs. 58.3%, respectively). The healthy weight loss programwas an efficient approach to obesity treatment.
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Introduction
According to the World Health Organization, obesity
has assumed epidemic proportions and become the lead-
ing public health issue1. Excessive weight is an impor-
tant risk factor for hypertension, hyperlipidemia, type 2
diabetes, some types of malignancies, and other disea-
ses1–3. Prevalent data on Croatia are not consolidated,
but according to one comprehensive study, 79.2% of men
and 49.9% of women have a body mass index (BMI) >25,
and 31.1% of men and 15.2% of women have a BMI >304,
whereas the standardized death from cardiovascular dis-
eases in 2001 was 91.7 per 100,000 population3.
Excessive body weight is an enormous health issue,
but still seems to be neglected in medical practice5,6. Na-
tional cardiovascular disease prevention strategies in
most countries strongly support programs introducing
healthy lifestyle as the most cost-effective method in re-
ducing cardiovascular morbidity and mortality7,8.
Use of drugs in obesity treatment is not advised in pa-
tients with the BMI <28 unless they suffer from condi-
tions caused by increased blood lipids, blood sugar, and
hypertension6. Lipase inhibitor, orlistat, accompanied by
a mildly hypocaloric diet helps reduce calories6–12. In ad-
dition, it reduces blood lipids, helps control glycemia, re-
duces insulin requirements, and helps normalize blood
pressure10,12. Prevention of cardiovascular risks should
therefore include reduction of weight, waist circumferen-
ce, BMI, and hyperlipidemia and hyperglycemia, which
are proven to be associated with high-fat diet. In other
words, by reducing fat intake and absorption, such treat-
ment algorithms can produce a beneficial domino-effect.
Behavioral approach to obesity treatment that aims
at changing eating habits and lifestyle has been widely
used13. When combined with pharmacological treatment,
it improves the weight loss14,15. Our outpatient Healthy
Weight Loss Program for obesity treatment is one of such
comprehensive approaches to obesity treatment. The
aim of this prospective study was to evaluate the efficacy,
safety, and tolerability of the program and to evaluate
the reduction in cardiovascular risk factors associated
with weight loss and use of a lipase inhibitor.
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Subjects and Methods
Subjects
All subjects who attended the initial Healthy Weight
Loss Program lectures about obesity, which has be orga-
nized by authors, at an out-of-hospital center in Rijeka
were eligible for the study. To be included in the study,
the subjects had to apply for participation in the pro-
gram, be aged between 18 and 65, and have a BMI over
30 or BMI over 28 and increased cholesterol, blood pres-
sure, and sugar. Of 900 who appeared at the initial lec-
tures, 725 decided to participate in the weight-loss pro-
gram, but only 627 went through a four-week period of
adjustment to a mild low-calorie diet and were included
in the study. Subjects who have a history of significant
cardiac, renal, hepatic, or gastrointestinal disorders were
excluded. Women were also excluded if they were preg-
nant or lactating. After the adjustment period subjects
were included in a six-month Healthy Weight Loss Pro-
gram and required to adhere to diet and attend work-
shops at an out-of-hospital center in Rijeka. However,
during the program period 151 subjects withdrew, and
476 subjects completed the study (Figure 1). The mean
age of subjects was 51.613.9 and there were almost
twice as many women as men.
Method
The Healthy Weight Loss Program consisted of educa-
tion about healthy weight loss, counseling, use of a lipase
inhibitor orlistat, and low-fat and low-calorie diet. Edu-
cational part included workshops organized by the study
authors, general practitioners, internal medicine physi-
cians, pharmacists, nutritionists, psychiatrists, and sports
medicine specialists, who were all part of the Healthy
Weight Loss Program. The workshops were interactive
and included lectures and discussions on reasons for obe-
sity, its complications, and treatment possibilities from
healthy diet and regular exercise to pharmacotherapy.
All study candidates received educational materials and
a weight loss guide Take Control Over Your Body Weight16.
Data on body height, body weight, waist circumference,
BMI, blood parameters, and blood were collected at base-
line. Body weight and BMI were also measured after
three and six months, whereas blood parameters and
blood pressure were measured only at the end of pro-
gram, i.e. after six months. Blood samples were tested in
the central laboratory of Thalassotherapy Center in Opa-
tija, a town near Rijeka.
During the six-month follow up, the subjects were on
a mild low-calorie diet containing no more than 30% of
fat. After four weeks of a low-calorie diet (1600 kcal/day,
three meals a day) and psychotherapeutic and nutri-
tional counseling, subjects started receiving orlistat (120
mg 3 times a day), a lipase inhibitor that reduces fat ab-
sorption in the gastrointestinal system by 30%9,10. No ap-
petite suppressors were allowed during the study. Month-
ly interviews with the subjects addressed the issues
related to the diet, everyday stress, physical activity, and
obstacles to weight loss and maintenance. Particular at-
tention was given to the analysis of failed attempts to
lose weight. The subjects were allowed to bring along
friends or family members to the interview. All subjects
maintained a diary in which they regularly recorded all
data related to the diet, physical activity, and difficulties
encountered. The follow up included a questionnaire for
all subjects with the following information to be filled in:
age, sex, accompanying diagnoses, lifestyle, body height,
body weight, body mass index, waist circumference, blood
pressure, triglycerides, cholesterol, glycemia, undesir-
able effects, subjective perception of treatment success.
These data were filled in on every monthly visit over the
six-month program. All subjects received detailed infor-
mation about healthy diet, physical activity, and weight
control program. Six months after the orlistat therapy
had finished, the subjects were contacted by phone or
mail to inquire about their body weight and satisfaction
with the weight loss program.
Statistical analysis
Data were presented as mean values with standard
deviations (SD) and analyzed with Students t-test. P
values <0.05 were considered statistically significant. All
statistical analyses were performed with SAS System
for Windows, version 8.2 (SAS Institute Inc., Cary, NC,
USA).
Results
The investigated parameters that were measured af-
ter 3 and 6 months of the study showed a significant de-
crease in comparison with baseline values in all subjects
(Table 1). The mean weight loss was 5.7  3.5 kg (6.3%)
after 3 months and 9.9  6.1 kg (10.9%) after 6 months
(P<0.001 for both; Table 1). After 6 months of the pro-
gram, systolic pressure decreased by 6.7%, diastolic pres-
sure by 4.2%, fasting blood glucose by 10.1%, and total
cholesterol by 9.8% on average (P<0.001 for all; Table 1).
After six months, all parameters significantly decreased
in both men and women. Although the decrease in all pa-
rameters except cholesterol was more pronounced in
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151 withdrew for:
- slow rate of weight loss (n=39)
- adverse orlistat events (n=15)
- failure to keep up with the program (n=54)
- non-compliance (n=15)
- other reasons (n=31)
627 enrolled
476 completed
312 women 164 men
Fig. 1. Flow diagram of study participants.
men than in women, there were no statistically signifi-
cant differences between the sexes (Table 2). Blood sugar
was the only parameter that decreased significantly more
in men than in women (0.91.2 vs 0.50.7, respectively,
P<0.001). Men lost 12.17.8 kg on average, whereas
women lost 8.84.6 kg. BMI decreased correspondingly,
i.e. by 3.92.5 for men and 3.21.7 for women. While tak-
ing orlistat, 57.4% of subjects were able to change their
dietary habits (reduced caloric intake and reduced per-
centage of fat). Undesirable effects of orlistat were recor-
ded in 50.4% of subjects. Most common complaints were
stool-related, as 41.4% subjects complained of steato-
rrhea, 19% of irregular stool, and 27.6% of other stool-
related problems. Also, 9% complained of thirst and 12%
of flatulence.
Nearly all subjects (95.7%) had attempted to lose
weight before entering the Healthy Weight Loss Pro-
gram, mostly by low-calorie diets (24.8%), changes in di-
etary habits (23.9%), over-the-counter weight loss drugs
(20%), exercise (15%), and acupuncture (15%). Most sub-
jects expressed preference for lipase inhibitor over ear-
lier weight loss attempts, 20.7% did not compare the ear-
lier and current treatment, 25.2% stated that the treat-
ments could not be compared, and 21.6% believed that
the lipase inhibitor treatment was more successful and
that the diet was normal insofar as it did not require any
particular effort to adhere to it (16.2%).
There were 151 subjects who did not complete the
program (Figure 1). The most common reasons for with-
drawal were inability to keep up with the program and
attend consultations with study physicians (35%), slow
rate of weight loss (25%), non-compliance (10%), and di-
arrhea as an adverse effect of orlistat (10%).
Six months after the discontinuation of lipase inhibi-
tor, 60.4% of subjects said they maintained the weight
achieved by the end of the program. As many as 98.1% of
subjects said that they felt healthier after having lost
weight. A little over the half of the subjects (53.5%) read
all educational materials received in the weight loss pro-
gram. A smaller number (15.0%) consulted the web pa-
ges of the weight loss program and 23.6% consulted the
study doctor over the phone.
The weight loss program with lipase inhibitor re-
ceived high scores from the subjects. On the scale from 1
(poor) to 5 (excellent) as many as 89.4% considered the
use of lipase inhibitor very good or excellent, and 83.8%
expressed the same level of satisfaction with the whole
weight loss program. More men than women were able to
maintain achieved weight loss after lipase inhibitor
treatment (70.6% vs. 58.3%, respectively). Women gave a
slightly higher mean score to the lipase inhibitor treat-
ment than men (4.45 vs. 4.30, respectively), whereas the
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TABLE 1
PARAMETERS MEASURED IN 476 SUBJECTS INCLUDED IN
THE HEALTHY WEIGHT LOSS PROGRAM AT BASELINE AND
AFTER 3 AND 6 MONTHS
Parameter
MeanSD
base-
line
3
months*
6
months*
Age (years) 51.613.9
Waist circumference (cm) 102.514.2 92.513.6
Height (cm) 168.58.9 168.58.9
Weight (kg) 90.416.5 84.715.1 80.514.1
Body mass index 31.85.0 29.84.6 28.34.3
Systolic pressure (mm Hg) 144.021.6 134.312.1
Diastolic pressure (mm Hg) 87.911.0 84.27.1
Blood glucose (mmol/L) 5.91.8 5.31.2
Cholesterol (mmol/L) 6.11.1 5.40.7
*P<0.001 for each measured parameter in comparison with ba-
seline values, t-test.
TABLE 2
PARAMETERS MEASURED IN MEN AND WOMEN INCLUDED IN THE HEALTHY WEIGHT LOSS PROGRAM AT BASELINE
AND AFTER 3 AND 6 MONTHS
Parameter
MeanSD
Men (n=164) Women (n=312)
baseline 3 months* 6 months* baseline 3 months* 6 months*
Age (years) 53.813.8 50.513.9
Waist (cm) 110.313.4 100.3712.8 98.412.8 89.5412.1
Height (cm) 175.98.4 175.98.4 164.66.3 164.66.3
Weight (kg) 101.417.5 94.515.7 89.314.5 84.612.7 79.611.9 75.811.5
BMI 32.95.6 30.65.1 28.94.6 31.24.6 29.44.3 28.04.1
Systolic pressure (mm Hg) 147.719.6 136.411.8 142.222.4 133.212.2
Diastolic pressure (mm Hg) 89.310.7 85.36.4 87.211.2 83.67.4
Blood glucose (mmol/L) 6.52.1 5.61.3 5.51.5 5.11.1
Cholesterol (mmol/L) 6.11.1 5.40.7 6.11.1 5.40.7
*P<0.001 for each measured parameter in comparison with baseline values, t-test.
weight loss program received similar scores by both
sexes. Nearly all subjects said that they would recom-
mend lipase inhibitor treatment (96.5%) and the Healthy
Weight Loss Program (96.0%) to their friends.
Discussion
According to our results, the six-month outpatient
Healthy Weight Loss Program consisting of diet, lipase
inhibitor orlistat, counseling, and education led to a sig-
nificant weight and BMI reduction and decrease in car-
diovascular risk factors in our subjects. Although half of
subjects complained of orlistat side effects, they were
overall very satisfied with the effects of the program. Al-
most two-thirds of subjects maintained the reduced weight
six month after the program had finished.
The role of drug treatment of obesity is still open and
inconclusive6. A great contribution to better understand-
ing of the efficacy and safety of drug use in the treatment
of obesity has come from a meta-analysis of different
medications for obesity treatment, which showed that
these drugs promote weight loss for at least 6 months
when used along with a diet (and possibly other behav-
ioral and exercise interventions)18. The amount of extra
weight loss attributable to these medications is modest,
<5 kg within a year, but it still may be clinically signifi-
cant. Different comparative studies into weight-loss me-
dication have shown that orlistat leads to weight reduc-
tion as effectively as other drugs19 and that it is more ef-
fective in reducing cholesterol, triglycerides, and blood
pressure than sibutramine18,20.
Findings from Ireland, Sweden, and Switzerland point
to the cost-effectiveness of obesity treatment with orli-
stat21–23. The base-case economic analysis revealed that
the costs per quality-adjusted life year gained were sub-
stantial, which is the reason why orlistat treatment is be-
ing reimbursed through health insurance in Sweden and
Switzerland to make it accessible to all who need it. An
Irish study used economic modeling techniques to evalu-
ate five clinical trials with 1386 subjects22. This model
showed that patients receiving orlistat for 12 months
had a mean weight loss of 11.6%, as opposed to 7.9% in
placebo controls. Patients who lost over 5% of their base-
line weight in the first three months, at the end of the
trial achieved a loss of 15.5%; this has become the thresh-
old for health insurance coverage for orlistat treatment.
Even though sophisticated models such as this are not
available in Croatia, a comparison of data used in calcu-
lations suggests that we would arrive at a similar conclu-
sion.
There is still the question of the long-term effects of
these drugs on health. Only a few studies attempted to
evaluate the effects of long-term weight loss programs on
health. One of these studies that evaluated long-term ef-
fects was XENDOS, a randomized placebo controlled
study of orlistat in combination with lifestyle changes
which enrolled over 3000 obese patients (mean BMI
37kg/sqm), of whom 21% were glucose-intolerant24. The
four-year follow up showed that orlistat-treated patients
lost more weight than placebo controls and had a 37%
lower risk of diabetes incidence. Even though only 52% of
orlistat-treated patients and 34% of placebo recipients
completed the treatment, this study corroborates the hy-
pothesis that long-term orlistat treatment may result in
a loss of body weight and help reduce obesity-related
health problems.
Another question that has remained unanswered is a
relative efficacy of obesity drugs. This also raises the
questions of whether a combination of drugs could result
in greater weight loss than single drugs25 and whether
the use of these drugs in combination with a more ag-
gressive lifestyle changes and low-calorie diet would be
more efficient than mild low-calorie diet. And last but
not the least, there is the question of optimal duration of
treatment. None of the randomized controlled studies
have offered more definitive answers to these questions,
but have left them to future clinical trials.
Some physicians believe that overweight patients have
to take medications for weight loss, which makes over-
weight a chronic disease, similar to hypertension26,27. In
that case, new information on long-term (longer than 12
month) efficacy and safety of obesity drugs is needed.
The XENDOS study of the efficacy and safety of orlistat
has so far been the longest such study of obesity drug
treatment24.
Most studies in obesity treatment have been con-
ducted by specialists in hospitals, even though this issue
requires a broader approach, including outpatient fol-
low-up by family physicians28,29. Our assumption was
that a comprehensive outpatient weight loss program
would result in a statistically and clinically significant
loss of weight and decrease in cardiovascular risks. The
results of our study showed a significant decrease in body
weight, BMI, systolic and diastolic blood pressure, fast-
ing blood glucose and total blood cholesterol in both men
and women included in the Healthy Weight Loss Pro-
gram. Our results are in accordance with previous stud-
ies that showed a behavioral approach to be successful in
the treatment of obesity28–38. A comprehensive review of
studies that followed long-term effects of weight loss on
hypertension between 1966 and 2001 has shown that a
10-kg weight loss decreased systolic and diastolic pres-
sure by 4–6 mmHg32. In our subjects who lost 5–10%, the
values of blood pressure, lipids, and glucose normalized
and they themselves reported feeling healthier.
Multidisciplinary approach not only enhances the ef-
fects of pharmacotherapy, but also helps maintain re-
duced body weight through a newly adopted lifestyle.
The results and experiences from our Healthy Weight
Loss Program confirm that treatment of obesity should
progress gradually and that the goals set should be real-
istic to avoid disappointment in patients and counter-ef-
fects of quick weight loss. We believe that family physi-
cians and pharmacists should have a more important
role in obesity treatment. They would be ideal partners
in designing and conducting similar healthy weight loss
programs, as they are the first to be approached by over-
weight patients who seek professional help. A number of
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studies have confirmed that it is primary care where
orlistat treatment programs are the successful form of
treatment of obesity and prevention of serious clinical
complications, including cardiovascular diseases28,29,33–37.
There are several limitations to our study. First, there
is a possibility of self-selection bias as subjects who at-
tended the introductory lessons could freely decide whe-
ther or not to join the program. Second, the subject attri-
tion rate was around 30%. The subjects dropped out from
the program either during one month of adjustment to a
mild low-calorie diet or during the program itself, but for
different reasons. Further limitation is use of self-re-
ported data on adherence to diet. However, the body
weight was measured at baseline and at the end of the
program and showed a significant decrease. The fourth
limitation is use of self-reported data on maintenance of
reduced weight during the follow-up six months after the
program had finished. Nevertheless, the participants re-
ported being satisfied with the results of the program.
In conclusion, our program of obesity treatment has
been proven to be efficient not only in weight loss, but
also in lowering high blood pressure, lipids, and sugar, all
known risk factors of cardiovascular diseases. This sug-
gest that reduced fat intake and absorption through food
can help prevent obesity-related cardiovascular compli-
cations and reduce morbidity and mortality from cardio-
vascular diseases as well as prolong life and working life
expectancy. For a definitive evaluation, our Healthy Weight
Loss Program based on low-fat diet, reduced fat absorp-
tion from food, and education about healthy lifestyle
needs to be continued and similar new projects started
with a large sample for a longer study period that would
definitely show if this treatment algorithm provides a
good basis for control of cardiovascular risk factors. A
project for prevention and treatment of obesity that
would involve family physicians, pharmacists, and other
interested parties from civil society to health insurance,
pension funds, and government institutions would be
able to properly address the issue of combating risk fac-
tors of the development of diabetes and cardiovascular
diseases as the leading causes of morbidity and mortality
today in developed and many developing countries.
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DJELOTVORNOST LIJE^ENJA PRETILOSTI PROGRAMOM ZDRAVOG MR[AVLJENJA:
HRVATSKO ISKUSTVO
S A @ E T A K
Procjenili smo u~inkovitost {estomjese~nog ambulantnog programa mr{avljenja temeljenog na kombinaciji zdrave
prehrane s redukcijom prehrambenih masno}a, psiholo{kog savjetovanja, tjelovje`be i lije~enja orlistatom. U studiju je
uklju~eno 476 ispitanika s indeksom tjelesne mase (ITM) iznad 30 ili ITM iznad 28 uz razvijenu hipertenziju, hiper-
kolesterolemiju ili poreme}aj glikemije nata{te. Na po~etku i kraju programa mjerena je tjelesna te`ina i ispitivani
~imbenici ukupnog kardiovaskularnog rizika. Nakon 4 tjedna niskokalorijske dijete (1600 kcal dnevno), uz odgova-
raju}e savjetovanje, ispitanici su zapo~eli terapiju orlistatom u dozi od 120 mg. Pad tjelesne te`ine nakon 6 mjeseci
iznosio je u prosjeku 10,9%, pad sistoli~kog krvnog tlaka 6,7%, dijastoli~kog 4,2%, glukoze nata{te 10,1% i ukupnog
kolesterola 9,8%. Samo devet ispitanika (1,89%) je imalo pote{ko}e u provo|enju programa. Mu{ki ispitanici su u odno-
su na `ene u zna~ajnijem postotku odr`avali postignutu tjelesnu te`inu tijekom idu}ih {est mjeseci (70,6% mu{karaca,
58,3% `ena). Primijenjeni program mr{avljenja uspjesno je potvrdio svoju djelotvornost u lije~enju pretilosti.
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